Val-Cit-PAB-MMAE
Based on 2 publication(s) in Google Scholar
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.98%
- No. CAS: 644981-35-1
- Fòrmula: C58H94N10O12
- Peso molecular:1123.43
-
Almacenamiento:
4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15575
VcMMAEDrug-Linker Conjugate for ADC -
HY-13631E
DeruxtecanDrug-Linker Conjugates for ADC -
HY-15162
Monomethyl auristatin EAntimitotic Agent -
HY-15578
McMMAFADC Drug-Linker -
HY-N0124
DioscinAnticancer Agent -
HY-100374G
Val-Cit-PAB-MMAE (GMP)Drug-Linker Conjugate For ADC -
HY-13631EG
Deruxtecan (GMP)Drug-Linker Conjugates for ADC -
HY-12460
SPDB-DM4ADC Linker -
HY-15575G
VcMMAE (GMP)Drug-Linker Conjugate for ADC -
HY-153032
Val-Ala-PAB-MMAE -
HY-153031
Val-Cit-PAB-ExatecanDrug-Linker Conjugate for ADC -
HY-101141
sulfo-SPDB-DM4Drug-Linker Conjugate for ADC
Publications Citing Use of MedChemExpress (MCE) Val-Cit-PAB-MMAE
More
Customer Validation & Images
-
In Vivo Efficacy Study
Ver todos los productos específicos de isoformas Drug-Linker Conjugates for ADC
More
Actividad biológica
Descripciòn
IC50 & Target
|
Auristatin |
In Vitro
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 644981-35-1
-
Appearance Solid
-
Peso molecular 1123.43
-
Fòrmula C58H94N10O12
-
Color White to off-white
-
SMILES
CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C3)=O)C)=O)=O)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pharm Res
A Newly Designed Antibody-drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers. [Abstract]2026 Jun 16. PMID: 42303884 -
Val-Cit-PAB-MMAE purchased from MedChemExpress. Usage Cited in: Patent. US20210093733A1.
The administration of Val-Cit-PAB-MMAE (OBI-998-TBR)-F (0.3 mg/kg; i.v.; once weekly for 4 weeks), Val-Cit-PAB-MMAE (OBI-998-TBR)-A and OBI-998-MCCA was associated with moderate and statistically significant anti-tumor activity compared to the vehicle control group over the course of the study.
Solvente y solubilidad
In Vitro:
DMSO : ≥ 110 mg/mL (97.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5.5 mg/mL (4.90 mM); Clear solution
This protocol yields a clear solution of ≥ 5.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (55.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8901 mL | 4.4507 mL | 8.9013 mL | 22.2533 mL |
| 5 mM | 0.1780 mL | 0.8901 mL | 1.7803 mL | 4.4507 mL | |
| 10 mM | 0.0890 mL | 0.4451 mL | 0.8901 mL | 2.2253 mL | |
| 15 mM | 0.0593 mL | 0.2967 mL | 0.5934 mL | 1.4836 mL | |
| 20 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL | |
| 25 mM | 0.0356 mL | 0.1780 mL | 0.3561 mL | 0.8901 mL | |
| 30 mM | 0.0297 mL | 0.1484 mL | 0.2967 mL | 0.7418 mL | |
| 40 mM | 0.0223 mL | 0.1113 mL | 0.2225 mL | 0.5563 mL | |
| 50 mM | 0.0178 mL | 0.0890 mL | 0.1780 mL | 0.4451 mL | |
| 60 mM | 0.0148 mL | 0.0742 mL | 0.1484 mL | 0.3709 mL | |
| 80 mM | 0.0111 mL | 0.0556 mL | 0.1113 mL | 0.2782 mL |
Val-Cit-PAB-MMAE Related Classifications
HY-100374 Related Classifications
Powered by Bioz